Zelluna Immunotherapy

ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT Namir Hassan, CEO, Zelluna Immunotherapy AS, commented: "This is an exciting moment for Zelluna and Ultimovacs. Zelluna is dedicated to pioneering a ground-breaking, novel and proprietary “off the shelf” cell therapy platform with a lead program nearing the clinic for the treatment of solid cancers. Ultimovacs, a publicly listed company, has built clinical execution expertise treating vast numbers of solid cancer patients. The two companies converge at the perfect time, combining complementary capabilities to take Zelluna’s world leading cell therapy platform to solid cancer patients. The combined company will also harness Zelluna’s established team of platform builders and business development to contribute in seeking to unlock the potential of Ultimovacs’ MultiClick platform. Together, by uniting strengths, and with a public listing and strong shareholder backing, these companies create a transformative force in the cell therapy field, poised to cure solid cancers, and take the lead on the global stage." https://lnkd.in/eQYecp-C

Science is always a team effort, and so is drug development. At Zelluna Immunotherapy, we have a great supportive team and our culture champions, Anja Oldenburg and Camilla Sletten, help us in practicing tools we learned in our Zelluna academy throughout the year. They are coming up with creative ideas engaging all of us and keeping our values very much alive.   For #Christmas, Anja and Camilla had yet another great idea. They made the best Christmas calendar ever. A Christmas calendar not only with some goodies and little decorations, but importantly with personalised cards for each of us comprising a word cloud with adjectives our colleagues described us with. Very touching and insightful at the same time.   So, each day, we can now look forward to possibly be the next ones being up and getting our little bag of surprise that's waiting for us. It spurs our Christmas spirit and #togetherness at the same time!   We wish you all a wonderful Christmas time and are thankful to our Zelluna culture champions.  

Zelluna at Cell 2024! We are delighted to participate at this years #Cell 2024. Our Head of CMC, Emilie Gauthy will be presenting on our worlds first #MAGE-A4 #TCR-NK and participate in an exciting panel discussion on the current state and future direction of cell therapies. Details as follows, on Friday 8th Nov: 12:05 Panel discussion: Technologies for cell therapy scale up and commercialization 14:45 Presentation: Bringing a MAGE-A4 Targeting, “off the shelf”, allogeneic TCR-NK cell therapy into the clinic: learnings through scale up manufacturing and regulatory interactions If you are attending, please do join Emilie Gauthy. #tcr #celltherapy #tcells #nkcells

Zelluna presenting at the 39th SITC! Zelluna Immunotherapy announces presentation of the worlds first MAGE-A4 TCR-NK cells at the 39th annual meeting of the Society for Immunotherapy of Cancer (SITC), 6-10th Nov, Houston, Texas. POSTER TITLE: Development of the first optimised “off the shelf” MAGE-A4 targeting TCR-NK cells for advancement into the clinic for the treatment of solid tumors PRESENTATION TIME AND LOCATION: Friday, 8th Nov, 2024 (12:15-1:45 pm and 5:30-7pm). Exhibit Halls A B George R. Brown Convention Center ABSTRACT NUMBER: 373 AUTHORS: Zara Hannoun, Anja Oldenburg, Artur Cieslar-Pobuda , Justyna Kmiecik, PhD , Giulia Malachin , Margherita Boieri , Maja Sandve , Sarah Vollmers , Martha Eimstad Haugstøyl , Inês Cardoso , Michelle L Saetersmoen, Frida H. Haugen , Dennis Clement , Pimthanya Wanichawan , Liliane C. , Pranav Oberoi, PhD , Luz Mora-Velandia , Anders Holm , Namir Hassan , Emilie Gauthy , Julia Ino , Sylvie Pollmann and Luise Weigand. Please join us if you are planning to be at the SITC! #SITC #39THSITC #SITC2024 #biotech #tcr #nk #mage #cellandgenetherapy #celltherapy #offtheshelfcellrherapy

Zelluna at the Life Science Investors Day. Our CEO Namir Hassan and COO/Head of BD Anders Holm were delighted to be part of the Life Science Investors Day in Heidelberg. We were honored to be selected to give a pitch to the many investors that were present. “Over the last years, therapies have become more and more precise which has advantages in safety, but leaves them vulnerable to tumor escape due to the diversity of solid tumors. This is one of the main challenges that limits effective treatment of solid cancers. To address this, therapies need to precisely target solid tumors but be broad in cancer recognition. This is why we are so excited by our TCR-NK platform, precise TCR targeting of solid tumors with broad cancer recognition by Natural Killer cells” said Namir Hassan. We continue to pioneer our TCR-NK platform with a lead MAGE-A4 targeting TCR-NK advancing towards an IND. #tcr #nk #cellandgenetherapy #celltherapy #biotech

Zelluna at the #ATE24 event! We are delighted to have presented our novel “off the shelf” cell therapy approach at the Advanced Therapies Europe event #ATE24. Our Head of Research Luise Weigand and Head of CMC Emilie Gauthy presented two talks entitled: Showcasing a novel “off the shelf” platform targeting heterogenous solid tumors And Bringing an allogeneic “off the shelf” TCR-NK cell therapy into the clinic: key learnings through development and scale-up of the manufacturing process A great opportunity to share with friends and colleagues the merits of TCR-NKs and hear about the progress in the field. There are exciting developments afoot and amongst them our worlds first MAGE-A4 TCR-NK cells offering the following benefits: ✅ Targeting MAGE-A4, a clinically valid target expressed across multiple solid cancers ✅ Combining #TCR with #NK receptor targeting to overcome tumour heterogeneity and HLA loss ✅ Scalable and accessible “off the shelf” cell product ✅ Favourable safety with the prospect of outpatient treatment We look forward to the next events! #zelluna #tcr #nkcells #cellandgenetherapy #celltherapy

First ever engineered TCR cell therapy approved today for a solid tumor. Today marks a pivotal milestone in the history of #TCR therapeutic development with the first ever TCR #celltherapy approved for a solid tumor. Huge congratulations to Adaptimmune for the approval of #TECELRA which is now available for adults with advanced MAGE-A4+ synovial sarcoma. This is an exciting moment for #Zelluna; we have firm belief in the potential of targeting MAGE-A4 for the treatment of solid tumors and are pioneering a novel approach using our proprietary #TCRNK platform to develop ZI-MA4-1: an affinity engineered TCR-NK product targeting MAGE-A4+ tumors. Our belief is that our novel MAGE-A4 TCR-NK cells offer the following benefits: ✅ Targeting MAGE-A4, a clinically valid target expressed across multiple solid cancers ✅ Combining #TCR with #NK receptor targeting to overcome tumour heterogeneity and HLA loss ✅ Scalable and accessible “off the shelf” product ✅ Favourable safety with the prospect of outpatient treatment We are heading for the clinic and the news on the approval of the first ever MAGE-A4 targeting TCR-Ts provides further wind in our sails. Importantly, all good news for #patients. #celltherapy #cellandgenetherapy #nkcells #offtheshelfcells #biotech

Energetic, vibrant and “cautious optimism”. Back from the 10th #LSX World Congress our CEO Namir Hassan and COO/Head of BD Anders Holm were delighted to see colleagues in the field and connect with others that share our enthusiasm on the novel #TCR-NK platform we are developing at #zelluna. “Cautious optimism” was the recurring sentiment on the sector; we share the optimism and are particularly excited to be advancing our worlds first MAGE-A4 TCR-NK towards IND. Great meetings, great discussions and a great event! #cellandgenetherapies #nks #tcr #biotech

AACR, thats a wrap! Another vibrant AACR, with great developments across the cancer therapeutics field and promising single agent and combination treatments reported. We were delighted by the huge engagement with our poster presentation; our team, Luise Weigand , Giulia Malachin and Sarah Vollmers talking through our latest data and charge towards the clinic with the worlds first “off the shelf” MAGE-A4 targeting TCR-NK cells for the treatment of solid tumors. Stay tuned for further updates on our pioneering journey over the course of the year! #cellandgenetherapy #nkcells #tcr #pioneering #biotech

Presenting the worlds first MAGE-A4 TCR-NK at the AACR 2024! #Zelluna are delighted to announce the presentation of the world’s first MAGE-A4 targeting #TCR-NK. For those heading to San Diego, join our Head of Research, Luise Weigand and senior scientists Giulia Malachin and Sarah Vollmers to hear our progress towards the clinic with our novel therapy. Details below: TITLE: Development of the first optimized “off the shelf” MAGE-A4 targeting TCR-NK cells for advancement into the clinic for the treatment of solid tumors SESSION CATEGORY: Immunology
 SESSION TITLE: CAR-NK, NK Engagers, and NK Modulators
 DATE AND TIME: Monday Apr 8, 2024 9:00 AM - 12:30 PM
 LOCATION: Poster Section 2
 POSTER BOARD NUMBER: 12
 PUBLISHED ABSTRACT NUMBER: 1329 #aacr2024 #tcr #cellandgenetherapies #nkcells #biotech #pioneering